Inhibikase Therapeutics, Inc.
IKT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $225,428 | $6,773 | $12,606 | $26,768 |
| - Cash | $56,491 | $9,165 | $7,189 | $40,750 |
| + Debt | $111 | $622 | $351 | $249 |
| Enterprise Value | $169,048 | -$1,770 | $5,769 | -$13,734 |
| Revenue | $0 | $261 | $123 | $3,101 |
| % Growth | -100% | 111% | -96% | – |
| Gross Profit | -$26 | -$13,358 | $117 | -$8,258 |
| % Margin | – | -5,127.8% | 94.6% | -266.4% |
| EBITDA | -$27,494 | -$19,912 | -$18,047 | $0 |
| % Margin | – | -7,643.9% | -14,620.4% | 0% |
| Net Income | -$27,520 | -$19,029 | -$18,054 | -$14,786 |
| % Margin | – | -7,304.8% | -14,625.9% | -476.9% |
| EPS Diluted | -1.16 | -3.57 | -4.26 | -4.88 |
| % Growth | 67.5% | 16.2% | 12.7% | – |
| Operating Cash Flow | -$19,148 | -$18,085 | -$17,351 | -$14,297 |
| Capital Expenditures | $0 | -$14 | -$243 | $0 |
| Free Cash Flow | -$19,148 | -$18,099 | -$17,594 | -$14,297 |